Chief Operating Officer · OnKure Therapeutics, Inc. (OKUR)

Michael Cruse

A named executive officer of OnKure Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$781,474

Salary $391,474Stock awards $0

FY2021: $1,496,036

3rd of 3 named executive officers at OnKure Therapeutics by FY2022 total.

3 named officers on file for OnKure Therapeutics, FY2022

Michael Cruse’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how OnKure Therapeutics’s whole pay program stands against its peers

  • OnKure Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OKUR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A).

Free

Get Michael Cruse’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Cruse compensation by year

OnKure Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as OnKure Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$300,000$391,474
Bonus$40,000$0
Stock awards$0$0
Option awards$1,072,736$246,000
Non-equity incentive$83,300$144,000
Pension and deferred compensation$0$0
All other$0$0
Total$1,496,036$781,474

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OnKure Therapeutics, Inc. DEF 14A filed April 26, 2023, accession 0000950170-23-014792, and prior-year filings. Open the filing on EDGAR.

How this page was built: the OnKure Therapeutics, Inc. filed document, accession 0000950170-23-014792. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

$1.5M
$781K
FY21
FY22
SalaryBonusNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU25,000$58,250—
Option20,313—$4.58
Option56,250—$6.69
Option114,738—$4.88
Option125,000—$1.80

Per the Outstanding Equity Awards at Fiscal Year-End table in OnKure Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

OnKure Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Gregory FlesherPresident and Chief Executive Officer$1,193,452
Ashley HallChief Development Officer$825,304
Michael Cruse · this pageChief Operating Officer$781,474

The full OnKure Therapeutics compensation record

free company brief

This page is one person within OnKure Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OnKure Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Cruse's compensation dossier · One-time report. No refunds.